Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells

British Journal of Pharmacology

Volumn 153, Issue 4, 2008, Pages 657-668

  Condorelli, F ^a   Gnemmi, I ^a   Vallario, A ^a   Genazzani, A A ^a   Canonico, P L ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Acetyl p53; Bcl 2 pathways: anti and proapoptotic; Butyric acid; HDAC inhibitors; Valproic acid

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CYCLIN DEPENDENT KINASE INHIBITOR 1; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; PROTEIN BCL 2; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN;

ACETYLATION; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL DEATH; CELL DIFFERENTIATION; CELL SURVIVAL; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOFLUOROMETRY; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ACETYLATION; ACTIVE TRANSPORT, CELL NUCLEUS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BUTYRATES; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; LYSINE; NEUROBLASTOMA; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION; VALPROIC ACID;

EID: 39449138853     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707608     Document Type: Article

References (47)

1. Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri DC (1998). Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 351: 882-883.
2. Ammanamanchi S, Freeman JW, Brattain MG (2003). Acetylated sp3 is a transcriptional activator. J Biol Chem 278: 35775-35780.
3. Barry MA, Behnke CA, Eastman A (1990). Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 40: 2353-2362.
4. Bowden CL (2003). Valproate. Bipolar Disord 5: 189-202.
5. Ciccarone V, Spengler BA, Meyers MB, Biedler JL, Ross RA (1989). Phenotypic diversification in human neuroblastoma cells: expression of distinct neural crest lineages. Cancer Res 49: 219-225.
6. Cirinna M, Trotta R, Salomoni P, Kossev P, Wasik M, Perrotti D et al. (2000). Bcl-2 expression restores the leukemogenic potential of a BCR/ABL mutant defective in transformation. Blood 96: 3915-3921.
7. Culmsee C, Mattson MP (2005). p53 in neuronal apoptosis. Biochem Biophys Res Commun 331: 761-777.
8. Davidoff AM, Pence JC, Shorter NA, Iglehart JD, Marks JR (1992). Expression of p53 in human neuroblastoma- and neuroepithelioma-derived cell lines. Oncogene 7: 127-133.
9. Fulda S, Debatin KM (2003). Apoptosis pathways in neuroblastoma therapy. Cancer Lett 197: 131-135.
10. Glozak MA, Sengupta N, Zhang X, Seto E (2005). Acetylation and deacetylation of non-histone proteins. Gene 363: 15-23.
11. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S et al. (2001). Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20: 6969-6978.
12. Gu W, Roeder RG (1997). Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90: 595-606.
13. Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS (2004). Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 64: 1079-1086.
14. Hall AC, Brennan A, Goold RG, Cleverley K, Lucas FR, Gordon-Weeks PR et al. (2002). Valproate regulates GSK-3-mediated axonal remodeling and synapsin I clustering in developing neurons. Mol Cell Neurosci 20: 257-270.
15. Hao Y, Creson T, Zhang L, Li P, Du F, Yuan P et al. (2004). Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J Neurosci 24: 6590-6599.
16. Heerdt BG, Houston MA, Augenlicht LH (1994). Potentiation by specific short-chain fatty acids of differentiation and apoptosis in human colonic carcinoma cell lines. Cancer Res 54: 3288-3293.
17. Hopkins-Donaldson S, Bodmer JL, Bourloud KB, Brognara CB, Tschopp J, Gross N (2000). Loss of caspase-8 expression in neuroblastoma is related to malignancy and resistance to TRAIL-induced apoptosis. Med Pediatr Oncol 35: 608-611.
18. Igney FH, Krammer PH (2002). Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2: 277-288.
19. Isoherranen N, Yagen B, Bialer M (2003). New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet? Curr Opin Neurol 16: 203-211.
20. Kawagoe R, Kawagoe H, Sano K (2002). Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways. Leuk Res 26: 495-502.
21. Komuro H, Hayashi Y, Kawamura M, Hayashi K, Kaneko Y, Kamoshita S et al. (1993). Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastomas. Cancer Res 53: 5284-5288.
22. Laeng P, Pitts RL, Lemire AL, Drabik CE, Weiner A, Tang H et al. (2004). The mood stabilizer valproic acid stimulates GABA neurogenesis from rat forebrain stem cells. J Neurochem 91: 238-251.
23. Legube G, Linares LK, Tyteca S, Caron C, Scheffner M, Chevillard-Briet M et al. (2004). Role of the histone acetyl transferase Tip60 in the p53 pathway. J Biol Chem 279: 44825-44833.
24. Legube G, Trouche D (2003). Regulating histone acetyltransferases and deacetylases. EMBO Rep 4: 944-947.
25. Lowe SW, Ruley HE, Jacks T, Housman DE (1993). p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967.
26. Mariadason JM, Barkla DH, Gibson PR (1997). Effect of short-chain fatty acids on paracellular permeability in Caco-2 intestinal epithelium model. Am J Physiol 272: G705-G712.
27. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK (2001). Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1: 194-202.
28. Marzio G, Wagener C, Gutierrez MI, Cartwright P, Helin K, Giacca M (2000). E2F family members are differentially regulated by reversible acetylation. J Biol Chem 275: 10887-10892.
29. Moll UM, LaQuaglia M, Benard J, Riou G (1995). Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci USA 92: 4407-4411.
30. Nicholson DW (2000). From bench to clinic with apoptosis-based therapeutic agents. Nature 407: 810-816.
31. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS (2001). Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276: 36734-36741.
32. Puthalakath H, Strasser A (2002). Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ 9: 505-512.
33. Reed JC, Meister L, Tanaka S, Cuddy M, Yum S, Geyer C et al. (1991). Differential expression of bcl2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin. Cancer Res 51: 6529-6538.
34. Savickiene J, Treigyte G, Borutinskaite V, Navakauskiene R, Magnusson KE (2006). The histone deacetylase inhibitor FK228 distinctly sensitizes the human leukemia cells to retinoic acid-induced differentiation. Ann NY Acad Sci 1091: 368-384.
35. Schiavone N, Rosini P, Quattrone A, Donnini M, Lapucci A, Citti L et al. (2000). A conserved AU-rich element in the 3′ untranslated region of bcl-2 mRNA is endowed with a destabilizing function that is involved in bcl-2 down-regulation during apoptosis. FASEB J 14: 174-184.
36. Sen S, D'Incalci M (1992). Apoptosis. Biochemical events and relevance to cancer chemotherapy. FEBS Lett 307: 122-127.
37. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X et al. (2001). Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409: 207-211.
38. Subramanian C, Opipari Jr AW, Bian X, Castle VP, Kwok RP (2005). Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 102: 4842-4847.
39. Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM et al. (1999). Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 397: 441-446.
40. Tweddle DA, Malcolm AJ, Bown N, Pearson AD, Lunec J (2001). Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. Cancer Res 61: 8-13.
41. Vogan K, Bernstein M, Leclerc JM, Brisson L, Brossard J, Brodeur GM et al. (1993). Absence of p53 gene mutations in primary neuroblastomas. Cancer Res 53: 5269-5273.
42. Waga S, Hannon GJ, Beach D, Stillman B (1994). The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369: 574-578.
43. Waterhouse NJ, Ricci JE, Green DR (2002). And all of a sudden it's over: mitochondrial outer-membrane permeabilization in apoptosis. Biochimie 84: 113-121.
44. Widlak P, Garrard WT (2005). Discovery, regulation, and action of the major apoptotic nucleases DFF40/CAD and endonuclease G. J Cell Biochem 94: 1078-1087.
45. Willis SN, Adams JM (2005). Life in the balance: how BH3-only proteins induce apoptosis. Curr Opin Cell Biol 17: 617-625.
46. Yuan PX, Huang LD, Jiang YM, Gutkind JS, Manji HK, Chen G (2001). The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J Biol Chem 276: 31674-31683.
47. Zhao Y, Lu S, Wu L, Chai G, Wang H, Chen Y et al. (2006). Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Mol Cell Biol 26: 2782-2790.